Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174036700> ?p ?o ?g. }
- W3174036700 abstract "Background: Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit for a wide range of cancer types. Because only a subset of patients benefit, there is a strong need for predictive biomarkers. The aim of this study was to analyze the predictive capacity of neutrophil-to-lymphocyte ratio (NLR) in cancer patients treated with ICI, and to analyze the predictive value of combining NLR with tumor mutational burden (TMB).Methods: Retrospective cohort study of patients treated during 2015-2018. A total of 1714 patients with 16 different cancer types, who had complete blood count within 30 days prior to first ICI infusion, and whose tumors underwent next-generation sequencing were included. Overall survival, progression-free survival, response to ICI, and clinical benefit (response or stable disease ≥6 months) were the primary endpoints.Findings: Patients with NLR in the top 20th percentile within cancer type had significantly poorer overall survival (HR = 2·17; 95% CI, 1·89-2·50; P<0·001), progression-free survival (HR = 1·60; 95% CI, 1·41-1·81; P<0·001), response rate (18% vs 29%; P<0·001), and clinical benefit rate (21% vs 35%; P<0·001). Consistent results were obtained stratifying by cancer type. In multivariable analyses, NLR and TMB demonstrated independent association with clinical benefit. A combined variable of NLR and TMB was strongly associated with outcome. The probability of clinical benefit from ICI was 4 times higher in the NLR-low/TMB-high group compared to the NLR-high/TMB-low group (OR = 3·88; 95% CI, 2·72-5·54; P<0·001).Interpretation: In cancer patients, higher NLR was associated with poorer survival and lower likelihood of response to ICI. NLR is a suitable candidate for a cost-effective and widely accessible predictive biomarker, and can be combined with TMB for additional predictive capacity.Funding Statement: Fundacion Alfonso Martin Escudero (to CV), NIH K08 DE024774 and R01 DE027738 (to LGTM), and the NIH/NCI Cancer Center Support Grant P30 CA008748.Declaration of Interests:DH receives funding from AstraZeneca. MAP reports consulting fees from BMS, Merck, Array BioPharma, Novartis, Incyte, NewLink Genetics, and Aduro, honoraria from BMS and Merck, and research support from RGenix, Infinity, BMS, Merck, Array BioPharma, Novartis, and AstraZeneca. ANS reports advisory board position with BMS, Immunocore, and Castle Biosciences, and institutional research support from BMS, Immunocore, and Xcovery. VPB is a recipient of an immuno-oncology translational research grant from Bristol-Myers Squibb and is an inventor on a patent application related to work on neoantigen modelling. AMC reports advisory board position with Springworks Therapeutics. JJS has received travel support from Intuitive Surgical Inc. for fellow education and has served as a clinical advisor to Guardant Health, Inc. SGP has a patent PCT/US2016/026717 Methods of Cancer Detection Using PARPIFL pending, holds equity in Summit Biomedical Imaging, has a patent US 10,016,238B2 Apparatus, system and method for providing laser steering and focusing for incision, excision and ablation of tissue in minimally-invasive surgery, and holds equity in ColdSteel Laser Inc. NR reports research support from Pfizer and BMS, and consulting fees from REPARE Therapeutics, Mirati Therapeutics and Illumina. AZ reports honoraria from Illumina. TAC acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai, has served as an advisor for Bristol-Myers Squibb, Illumina, Eisai, and An2H, holds equity in An2H, and is a co-founder of Gritstone Oncology and holds equity. LGTM reports laboratory research funding from Illumina, Inc. and AstraZeneca. Ethics Approval Statement: The study was approved by the Memorial Sloan Kettering Cancer Center institutional review board (IRB)." @default.
- W3174036700 created "2021-07-05" @default.
- W3174036700 creator A5000566519 @default.
- W3174036700 creator A5001058762 @default.
- W3174036700 creator A5002954478 @default.
- W3174036700 creator A5004342511 @default.
- W3174036700 creator A5010249092 @default.
- W3174036700 creator A5011325668 @default.
- W3174036700 creator A5013778834 @default.
- W3174036700 creator A5023007737 @default.
- W3174036700 creator A5025014871 @default.
- W3174036700 creator A5027048828 @default.
- W3174036700 creator A5031748760 @default.
- W3174036700 creator A5034626553 @default.
- W3174036700 creator A5037092952 @default.
- W3174036700 creator A5040291209 @default.
- W3174036700 creator A5041344703 @default.
- W3174036700 creator A5046345178 @default.
- W3174036700 creator A5050613273 @default.
- W3174036700 creator A5052610122 @default.
- W3174036700 creator A5060380153 @default.
- W3174036700 creator A5070161517 @default.
- W3174036700 creator A5073798092 @default.
- W3174036700 creator A5075136197 @default.
- W3174036700 creator A5078178893 @default.
- W3174036700 creator A5078966058 @default.
- W3174036700 creator A5078981086 @default.
- W3174036700 creator A5080223712 @default.
- W3174036700 creator A5084443648 @default.
- W3174036700 creator A5089840300 @default.
- W3174036700 creator A5089999939 @default.
- W3174036700 date "2020-01-01" @default.
- W3174036700 modified "2023-09-26" @default.
- W3174036700 title "Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictor of Survival and Response to Therapy in Patients Treated with Immune Checkpoint Inhibitors" @default.
- W3174036700 doi "https://doi.org/10.2139/ssrn.3578798" @default.
- W3174036700 hasPublicationYear "2020" @default.
- W3174036700 type Work @default.
- W3174036700 sameAs 3174036700 @default.
- W3174036700 citedByCount "0" @default.
- W3174036700 crossrefType "journal-article" @default.
- W3174036700 hasAuthorship W3174036700A5000566519 @default.
- W3174036700 hasAuthorship W3174036700A5001058762 @default.
- W3174036700 hasAuthorship W3174036700A5002954478 @default.
- W3174036700 hasAuthorship W3174036700A5004342511 @default.
- W3174036700 hasAuthorship W3174036700A5010249092 @default.
- W3174036700 hasAuthorship W3174036700A5011325668 @default.
- W3174036700 hasAuthorship W3174036700A5013778834 @default.
- W3174036700 hasAuthorship W3174036700A5023007737 @default.
- W3174036700 hasAuthorship W3174036700A5025014871 @default.
- W3174036700 hasAuthorship W3174036700A5027048828 @default.
- W3174036700 hasAuthorship W3174036700A5031748760 @default.
- W3174036700 hasAuthorship W3174036700A5034626553 @default.
- W3174036700 hasAuthorship W3174036700A5037092952 @default.
- W3174036700 hasAuthorship W3174036700A5040291209 @default.
- W3174036700 hasAuthorship W3174036700A5041344703 @default.
- W3174036700 hasAuthorship W3174036700A5046345178 @default.
- W3174036700 hasAuthorship W3174036700A5050613273 @default.
- W3174036700 hasAuthorship W3174036700A5052610122 @default.
- W3174036700 hasAuthorship W3174036700A5060380153 @default.
- W3174036700 hasAuthorship W3174036700A5070161517 @default.
- W3174036700 hasAuthorship W3174036700A5073798092 @default.
- W3174036700 hasAuthorship W3174036700A5075136197 @default.
- W3174036700 hasAuthorship W3174036700A5078178893 @default.
- W3174036700 hasAuthorship W3174036700A5078966058 @default.
- W3174036700 hasAuthorship W3174036700A5078981086 @default.
- W3174036700 hasAuthorship W3174036700A5080223712 @default.
- W3174036700 hasAuthorship W3174036700A5084443648 @default.
- W3174036700 hasAuthorship W3174036700A5089840300 @default.
- W3174036700 hasAuthorship W3174036700A5089999939 @default.
- W3174036700 hasConcept C121608353 @default.
- W3174036700 hasConcept C126322002 @default.
- W3174036700 hasConcept C143998085 @default.
- W3174036700 hasConcept C167135981 @default.
- W3174036700 hasConcept C203092338 @default.
- W3174036700 hasConcept C2777761686 @default.
- W3174036700 hasConcept C2778963024 @default.
- W3174036700 hasConcept C2780739268 @default.
- W3174036700 hasConcept C3019894029 @default.
- W3174036700 hasConcept C535046627 @default.
- W3174036700 hasConcept C71924100 @default.
- W3174036700 hasConceptScore W3174036700C121608353 @default.
- W3174036700 hasConceptScore W3174036700C126322002 @default.
- W3174036700 hasConceptScore W3174036700C143998085 @default.
- W3174036700 hasConceptScore W3174036700C167135981 @default.
- W3174036700 hasConceptScore W3174036700C203092338 @default.
- W3174036700 hasConceptScore W3174036700C2777761686 @default.
- W3174036700 hasConceptScore W3174036700C2778963024 @default.
- W3174036700 hasConceptScore W3174036700C2780739268 @default.
- W3174036700 hasConceptScore W3174036700C3019894029 @default.
- W3174036700 hasConceptScore W3174036700C535046627 @default.
- W3174036700 hasConceptScore W3174036700C71924100 @default.
- W3174036700 hasLocation W31740367001 @default.
- W3174036700 hasOpenAccess W3174036700 @default.
- W3174036700 hasPrimaryLocation W31740367001 @default.
- W3174036700 hasRelatedWork W10690345 @default.
- W3174036700 hasRelatedWork W1202678 @default.
- W3174036700 hasRelatedWork W12927781 @default.
- W3174036700 hasRelatedWork W17437393 @default.
- W3174036700 hasRelatedWork W1756981 @default.
- W3174036700 hasRelatedWork W1849033 @default.